Part 1 obgyn notes Sri Lanka
    NOTES for part 1
    /
    pharmacology
    /
    drugs in PV bleeding

    drugs in PV bleeding

    Owner
    U
    Untitled
    Verification
    Tags

    Tranexamic Acid (TXA)

    Core Logic (Why it works)

    • Bleeding continues when clots are broken down too fast
    • Tranexamic acid prevents clot breakdown
    • So → blood loss reduces without affecting ovulation or hormones

    Mechanism of Action

    • Synthetic lysine analogue
    • Competitively inhibits plasminogen → plasmin conversion
    • Blocks plasmin binding to fibrin
    • Result: stabilizes formed clots (antifibrinolytic)

    Pharmacological Effect

    • ↓ fibrinolysis
    • ↓ menstrual blood loss by 40–60%
    • No effect on coagulation cascade initiation
    • No effect on ovulation or endometrium growth

    Clinical Uses

    • Menorrhagia / Heavy menstrual bleeding
    • Acute bleeding (trauma, surgery, dental)
    • Post-partum hemorrhage (adjunct)
    • Epistaxis, hematuria (selected cases)

    Dose (Gynecologic use – exam safe)

    • 1 g orally 3–4 times daily
    • Given only during menstruation
    • Usually for up to 5 days

    Adverse Effects

    • Nausea, vomiting, diarrhea
    • Dizziness
    • Rare: visual disturbances
    • Thromboembolism (rare but exam-important)

    Contraindications

    • Active thromboembolic disease
    • History of DVT / PE
    • Subarachnoid hemorrhage
    • Severe renal impairment (dose adjust)

    Drug Interactions

    Combined oral contraceptives → ↑ thrombosis risk

    • Other pro-coagulant states

    Exam Logic Lock

    • Heavy bleeding + normal hormones → Tranexamic acid
    • Bleeding problem, not ovulatory problem
    • Works during bleeding, not preventive

    Mefenamic Acid

    Core Logic (Why it works)

    • Menstrual bleeding + pain is driven by excess prostaglandins
    • Prostaglandins cause:
      • Vasodilation
      • Uterine contractions
    • Block prostaglandins → less pain + less bleeding

    Mechanism of Action

    • NSAID
    • Inhibits COX-1 and COX-2
    • ↓ Prostaglandin synthesis in endometrium

    Pharmacological Effect

    • ↓ uterine contractility
    • ↓ endometrial vasodilation
    • ↓ menstrual blood loss by 20–30%
    • Analgesic + anti-inflammatory

    Clinical Uses

    • Primary dysmenorrhea
    • Mild–moderate menorrhagia
    • Pelvic pain associated with menses

    Dose

    • 500 mg initially
    • Then 250–500 mg every 6–8 hours
    • Start at onset of menstruation
    • Short-term use only

    Adverse Effects

    • Gastritis
    • Peptic ulcer
    • Nausea
    • Renal impairment (NSAID class)
    • Platelet inhibition (mild)

    Contraindications

    • Peptic ulcer disease
    • Chronic kidney disease
    • NSAID hypersensitivity
    • Bleeding disorders (relative)

    Drug Interactions

    • Anticoagulants → ↑ bleeding risk
    • Other NSAIDs
    • Steroids → ↑ GI bleed

    Exam Logic Lock

    • Pain + bleeding → NSAID
    • Best when dysmenorrhea is prominent
    • Less effective than TXA for pure bleeding

    Norethisterone

    Core Logic (Why it works)

    • Irregular/heavy bleeding often due to unopposed estrogen
    • Estrogen thickens endometrium → unstable shedding
    • Progestin:
      • Stabilizes endometrium
      • Converts it to secretory phase
      • Controls timing of bleeding

    Mechanism of Action

    • Synthetic progestogen
    • Suppresses endometrial proliferation
    • Induces secretory transformation
    • At higher doses:
      • Suppresses LH/FSH
      • Inhibits ovulation

    Pharmacological Effect

    • ↓ endometrial thickness
    • ↓ bleeding
    • Cycle control
    • Can delay menstruation

    Clinical Uses

    • Dysfunctional uterine bleeding
    • Anovulatory cycles
    • Endometriosis
    • Postpone menstruation
    • Luteal phase support (selected cases)

    Dose (exam standard patterns)

    • DUB: 5 mg 2–3 times daily
    • Given for 10–21 days
    • Withdrawal bleeding occurs after stopping

    Adverse Effects

    • Weight gain
    • Acne
    • Mood changes
    • Breast tenderness
    • Breakthrough bleeding
    • Androgenic effects (dose-dependent)

    Contraindications

    • Pregnancy
    • Active liver disease
    • Breast cancer
    • Thromboembolic disorders
    • Undiagnosed vaginal bleeding

    Drug Interactions

    • Enzyme inducers (rifampicin, phenytoin) ↓ effect
    • Combined hormonal therapies

    Exam Logic Lock

    • Irregular cycles / anovulation → Progestin
    • Endometrial problem, not clot or prostaglandin problem
    • Used to regulate, not for acute bleeding only

    One-Look Comparison (High-Yield)

    Feature
    Tranexamic Acid
    Mefenamic Acid
    Norethisterone
    Primary action
    Antifibrinolytic
    COX inhibition
    Progestin
    Targets
    Clot breakdown
    Prostaglandins
    Endometrium
    Best for
    Pure heavy bleeding
    Pain + bleeding
    Irregular / anovulatory
    Hormonal effect
    None
    None
    Yes
    Ovulation effect
    No
    No
    Yes (high dose)

    Final Exam Reflex Line

    • Heavy bleeding only → Tranexamic acid
    • Pain + bleeding → Mefenamic acid
    • Irregular cycles / DUB → Norethisterone

    Abnormal Uterine Bleeding – Drug Comparison (Exam Gold Table)

    Feature
    Tranexamic Acid (TXA)
    Mefenamic Acid
    Norethisterone
    Drug class
    Antifibrinolytic
    NSAID
    Progestin
    Core problem addressed
    Excess clot breakdown
    Excess prostaglandins
    Endometrial instability (unopposed estrogen / anovulation)
    Primary target
    Plasminogen / plasmin
    COX-1 & COX-2
    Endometrium ± HPO axis
    Mechanism
    Blocks plasminogen → plasmin conversion → stabilizes fibrin clot
    ↓ Prostaglandin synthesis
    Converts proliferative → secretory endometrium
    Effect on fibrinolysis
    ↓↓↓ (major effect)
    No
    No
    Effect on prostaglandins
    No
    ↓↓↓
    Indirect ↓
    Effect on endometrium
    None
    Minimal
    Direct stabilization
    Effect on ovulation
    ❌ No
    ❌ No
    ✅ Yes (at high dose)
    Hormonal effect
    None
    None
    Present
    Reduction in menstrual blood loss
    40–60%
    20–30%
    Variable
    Effect on dysmenorrhea
    ❌ No
    ✅ Yes (best)
    Mild
    Timing of use
    Only during menstruation
    From onset of menses
    Given for days–weeks
    Typical exam dose
    1 g PO 3–4×/day × ≤5 days
    500 mg stat → 250–500 mg 6–8-hourly
    5 mg 2–3×/day for 10–21 days
    Best indication
    Pure heavy bleeding with normal cycles
    Pain + bleeding
    Irregular / anovulatory bleeding (DUB)
    Role in cycle control
    ❌ None
    ❌ None
    ✅ Yes
    Use to delay menses
    ❌ No
    ❌ No
    ✅ Yes
    Common adverse effects
    Nausea, dizziness
    Gastritis, renal effects
    Weight gain, acne, mood change
    Major exam-important risk
    Thromboembolism (rare)
    GI bleed
    Thrombosis, androgenic effects
    Key contraindication
    DVT / PE, active thrombosis
    Peptic ulcer, CKD
    Pregnancy, breast CA, liver disease
    Key drug interaction
    COCs ↑ thrombosis risk
    Anticoagulants ↑ bleed
    Enzyme inducers ↓ effect

    Ultra-Short Exam Reflex (1-line memory)

    • Bleeding only → Tranexamic acid
    • Pain + bleeding → Mefenamic acid
    • Irregular / anovulatory bleeding → Norethisterone